Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombigain
- Development stage
- Unknown
- Lead developer
- PRUDENTIX
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Recombigain is a human recombinant amelogenin therapy developed by Prudentix for hard and soft tissue regeneration in dentistry, specifically for treating tooth-supporting tissues lost to chronic periodontitis. The active ingredient is rAmelX, a highly purified human recombinant amelogenin produced in an *E. coli* expression system. Formulated as a patented, thermo-sensitive gel using poloxamer 407, Recombigain is liquid at refrigerated temperatures and transforms into a thick, viscous mucoadhesive gel at body temperature. It is applied topically in a single step as an adjunct to periodontal surgery. Amelogenin acts as an attachment factor and chemoattractant for mesenchymal stem cells, promoting their proliferation and differentiation to regenerate alveolar bone, periodontal ligament, connective tissue, and cementum.
- Brand names
- Recombigain
- Other names
- human recombinant amelogeninrAmelXrecombinant human amelogenin
02
Targets
CD63 (Lysosome-associated membrane glycoprotein 3)LAMP1 (Lysosomal-associated membrane protein 1)
Beyond the preview
Go deeper on Recombigain.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombigain.